MedTrace Logo

Eyelash Effect Evaluation for Premium Rejuvenation Eyelash Serum

NCT07271199 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-12

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of the Premium Rejuvenation Eyelash Serum on eyelashes and the surrounding periorbital skin. A total of 30 healthy female participants, aged 18 to 60, will be recruited and randomly assigned to two groups to receive either test product or placebo at 1:1 ratio. Participants will apply the product twice daily for 56 days (8 weeks), with eyelash and periorbital skin conditions assessed at multiple time points using non-invasive measurements. Key parameters include eyelash density, eyelash length, and overall periorbital skin condition. At the end of the study (Day 56), participant will be asked to fill out a questionnaire on the usage of the intervention and self evaluation of eyelash condition.

Conditions

  • Skin Condition
  • Eyelash Growth
  • Eyelashes
  • Skin Health
  • Hair Health

Interventions

OTHER

Placebo control

Placebo Control (Base Formula without active ingredients). After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat application twice daily, in the morning and evening.

OTHER

Experimental formula

Base formula with ginger (Zingiber officinale)-derived extracellular vesicle, turmeric (Curcuma longa)-derived extracellular vesicles, insulin growth factor-1 (IGF-1), and fibroblast growth factor-7 (FGF-7). After thoroughly cleansing the face and removing contact lenses (if applicable), apply 1 mL of the serum evenly to the base of the eyelashes. Allow the serum to absorb for a few minutes. Repeat this application twice daily, in the morning and evening.

Sponsors & Collaborators

  • Schweitzer Biotech Company

    collaborator UNKNOWN

  • Hungkuang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-05-26
Completion
2026-05-26

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07271199 on ClinicalTrials.gov